ZOE Zoetis Inc.

In the most recent trading session, Zoetis (ZTS) closed at $70.27, indicating a -1.87% shift from the previous trading day.

Burry’s indirect AI bet is ERO, saying that data-center construction will intensify copper demand while new mines take 18 years to reach production.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Zoetis (ZTS) closed at $71.4 in the latest trading session, marking a -2.22% move from the prior day.

Zoetis is back in focus after analysts cut their fair value estimate from US$114.76 to US$96.00, a reduction of around 16% that resets expectations around what the stock might be worth. This shift lines up with more mixed analyst commentary, where many firms are trimming price targets and some are also dialing back their ratings as they reassess clinic trends, competition and pricing. Read on to see what is driving the updated narrative and how you can track the next moves in Zoetis. Stay...

Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and intensified competition in dermatology and parasiticides. Speaking at a Morgan Stanley conference, CEO Kri

Michael Burry says Lululemon’s valuation has become increasingly attractive and sees Zoetis as “very cheap” despite the risk of further downside.

Rock-bottom prices don’t always mean rock-bottom businesses. The stocks we’re examining today have all touched their 52-week lows, creating a classic investor’s dilemma: bargain opportunity or value trap?

If you hold Pfizer (PFE) or Zoetis (ZTS), you hold the same idea: a branded medicine becomes a standard of care and keeps earning for years, in people or in animals. That is where it stops. Pfizer is buying replacements for older drugs losing exclusivity. Zoetis is cutting its effective price to keep the franchises it has. Same bet, two opposite defenses.

Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the “Impax US Sustainable Economy Fund”. The letter can be downloaded here. The US Sustainable Economy portfolio outperformed the Russell 1000 in Q2 2026, with Institutional Class at 17.96%, Investor Class at 17.95%, and Class A at […]

Zoetis has significantly lagged the broader market over the past year, while analysts remain cautiously optimistic about its outlook.

The AI rally put Burry’s bearish stance under pressure as Palantir, CoreWeave, Oracle, Micron, Tesla, Nebius and Nvidia all climbed during August.

Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi

Moby summary of Phibro Animal Health Corporation's Q4 2026 earnings call

The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S. revenue and an 11% drop in domestic companion-animal product sales, Simparica Trio received Emergency Use Authorization to treat New World screwworm infestations in dogs and puppies. The treatment […]

Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand. Fiscal Q2 2026 revenue remained flat at $2.5 billion and declined 1% on an organic operational basis, as pressure in the U.S. companion-animal market […]

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Zoetis stock has had a tough run over the last few years, yet the current valuation checks suggest the shares may now be pricing in a lot of that bad news. After a prolonged slide, the question is whether the current market price properly reflects Zoetis' earnings power and risks. Over the past 5 years, Zoetis shareholders have seen the share price decline about 61.8%, which points to a significant reset in expectations. Recent investor focus is on how competition and softer pet care...

Zoetis recently received an Emergency Use Authorization from the U.S. FDA for its Simparica Trio chewable to treat life-threatening New World screwworm infestations in dogs and puppies, while also appointing experienced healthcare executive Jay Saccaro as its new Chief Financial Officer and Chief Operating Officer. At the same time, Zoetis lowered its full-year 2026 revenue and earnings guidance, signaling a more cautious outlook even as it expands the clinical reach of one of its flagship...

Phibro Animal Health's Animal Health growth and global reach support its outlook, but Brazil's antimicrobial transition and trade risks cloud near-term prospects.

These stocks have been generous with their dividend increases, and more may be on the way.

William Grogan will take over the chief finance job vacated by Jay Saccaro. Stifel analysts called Grogan’s “no-nonsense” mindset on setting expectations a strength.

Zoetis (NYSE:ZTS) is an animal health company. Michael Burry is long the stock, several media outlets reported, citing his Substack disclosures. The stock is down about 40% so far this year. Let’s break down whether it’s worth buying. Why Burry Likes It Burry’s pitch is simple. Zoetis has dropped more than 70% from its 2021 […]

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Zoetis delivered flat revenue in Q2, missing Wall Street expectations, while its adjusted earnings per share slightly exceeded consensus. The market’s positive reaction was underpinned by management’s acknowledgment of intensifying competitive pressures in key Companion Animal categories and ongoing declines in U.S. veterinary clinic visits. CEO Kristin Peck noted, “Veterinary clinic visits declined across markets, extending a multiyear trend that has occurred alongside price increases that have

Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q2 2026 investor letter. A copy of the letter can be downloaded here. Polen Focus Growth returned 6.33% (net of fees) in the second quarter of 2026, significantly underperforming the Russell 1000 Growth Index’s 16.74% gain, as the market rally remained narrowly focused on AI […]

The FDA authorized Zoetis’s Simparica TRIO—already sold since 2020 for heartworm, fleas and ticks—for treating New World screwworm in dogs and puppies.

U.S. companion animal demand weakened, but livestock and diagnostics surged.

'The Big Short' investor is betting against AI-linked names even as he sees strong demand for compute as a potential warning sign for the sector.

Famed "Big Short" investor Michael Burry buys new out-of-the-money puts on Palantir and adds to his Zoetis stake.

Zoetis has considerably underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Brown Advisory, an investment management company, released its “Brown Advisory Global Leaders Strategy” for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory’s Global Leaders Strategy delivered a net return of 4.6% in the second quarter of 2026, underperforming its benchmark, the MSCI ACWI Net Index, […]